Suzuki T, Nozawa T, Sobajima M, et al. Atorvastatin-induced changes in plasma coenzyme q10 and brain natriuretic peptide in patients with coronary artery disease. Int Heart J. 2008 Jul;49(4):423-433.
http://www.jstage.jst.go.jp/article/ihj/49/4/49_423/_article
http://www.jstage.jst.go.jp/article/ihj/49/4/423/_pdf
+++++
Int Heart J. 2008 Jul;49(4):423-33.
Atorvastatin-induced changes in plasma coenzyme Q10 and brain natriuretic peptide in patients with coronary artery disease.
Suzuki T, Nozawa T, Sobajima M, Igarashi N, Matsuki A, Fujii N, Inoue H.
Second Department of Internal Medicine, Graduate School of Medicine, University of Toyama, Toyama, Japan.
The beneficial effects of statins in patients with coronary artery disease (CAD) may be balanced by concerns that statins can depress production of ubiquinone (CoQ10), which serves as a component of mitochondrial energy production and an antioxidant. Accordingly, the effects of atorvastatin (ATO)-induced changes in plasma CoQ10 on BNP and oxidative stress were investigated. In 29 patients with CAD, the plasma levels of CoQ10 and BNP and urinary excretion of 8-iso-prostaglandin F2alpha (8-iso-PGF) were determined before and after 3-month treatment with ATO. Ten patients had received pravastatin and 10 patients fluvastatin, while 9 patients had not received any statin before ATO. There was a linear correlation between ATO-induced changes in total cholesterol and CoQ10 (r = 0.632, P
PMID: 18753726